
Infectious Disease Treatments on FDA’s Watchlist for Q2 2025
As we enter the second quarter of 2025, the FDA is reviewing treatments in infectious disease. Novavax is seeking full approval for its COVID-19 vaccine, Merck’s monoclonal antibody for RSV prevention is under review, and Innoviva has applied an oral …